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ABSTRACT
Background: Ovarian cancer is the most lethal gynecologic malignancy. Despite
modest clinical improvements with anti-VEGF antibody (AVA) therapy, adaptive
resistance is nearly ubiquitous and additional therapeutic options are limited. A
dependence on glutamine metabolism, via the enzyme glutaminase (GLS), is a known
mechanism of adaptive resistance.
Purpose: To assess the efficacy of a glutaminase inhibitor as a means of exploiting the
metabolic vulnerability of glutamine dependence that develops as a result of adaptive
resistance to AVA therapy.
Experimental Design: We used a glutaminase inhibitor (GLSi) synthesized at MD
Anderson Cancer Center for all in vitro and in vivo experiments. We first assessed the in
vitro effect of culturing ovarian cancer cell lines under hypoxic conditions and
subsequently evaluated the metabolic adaptations that occurred as a result of this
metabolic stress. Following this, we analyzed the effects of GLSi treatment on these
cells. We then performed a series of in vivo experiments to determine the efficacy of
GLSi therapy and the downstream metabolic impact of treatment. Statistical analysis of
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all experiments was performed using Student t test or Mann-Whitney test, as applicable,
with a p value < 0.05 considered significant.
Results: Eight ovarian cancer cell lines were screened for glutaminase (GLS) expression
with the SKOV3 cell line demonstrating the greatest expression and therefore it was
utilized for all in vivo experiments. We demonstrated a significant sensitivity of these
GLS-expressing cells to GLSi treatment in vitro. AVA treatment in vivo was associated
with an increased abundance of glutamine in tumor tissue. Treatment with a GLSi in this
setting led to a reduction in tumor growth and decreased metabolic conversion of
pyruvate to lactate as assessed by hyperpolarized magnetic resonance spectroscopy.
Furthermore, GLSi therapy initiated after the emergence of AVA resistance restored
sensitivity to AVA therapy as evidenced by a reduction in tumor volume and a
prolongation of survival of the orthotopic mouse model.
Conclusions: Our analyses indicate that alterations in glutamine metabolism occur in
adaptive resistance to AVA therapy and that this can be targeted by GLSi therapy. The
combination of AVA and GLSi in vivo led to robust anti-tumor responses supporting the
inclusion of this combination of therapy in future clinical trials in the setting of AVA
resistance.
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BACKGROUND AND INTRODUCTION
Epidemiology of ovarian cancer
Ovarian cancer most frequently presents as an advanced stage disease
making it the most lethal of all gynecologic malignancies, claiming the lives of more
than 14,000 women each year.1,4 Contributing to the lethality is the fact that the early
symptoms of ovarian cancer are subtle and include abdominal bloating, changes in
bowel habits, weight gain, and menstrual irregularities.5 Given that ovarian cancer
is a disease of peri- or post-menopausal women6 there is often a misattribution of
these associated symptoms to the menopausal transition, or as a manifestation of
stress or other benign gastroenterological conditions such as irritable bowel
syndrome.7 As such, nearly one-fourth (22%) of patients ultimately diagnosed with
ovarian cancer receive a diagnosis of a gastroenterological problem in the year
preceding the final correct diagnosis.7 Generally, more severe symptoms that would
prompt a patient to seek an urgent medical evaluation occur only after the disease
has become metastatic.5 In fact, small retrospective studies have estimated that
nearly 90% of women who are diagnosed with ovarian cancer experience one or
more diagnostic delays due to the vague nature of their symptoms.8 These sorts of
diagnostic delays therefore contribute to the increased incidence of advanced stage
disease at diagnosis. Unfortunately, the overwhelming majority of patients (>80%)
are diagnosed with distant metastatic spread and this translates to a 5-year survival
of approximately 30% (Figure 1).1

Despite these dismal numbers, an under-

appreciated fact is that disease prevalence is increasing. Estimates by the
Surveillance, Epidemiology, and End Results (SEER) program of the National
Cancer Institute (NCI) indicate that the prevalence of ovarian cancer cases in the
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United States is approximately 250,000. This represents a 10-fold increase over
annualized incidence that has increased over 25% in the last five years.1 Much of
this comes as a result of drugs extending PFS without increasing cure rates.
Therefore, new drugs and combinations could have a meaningful impact for women
with ovarian cancer.

Five year Relative Survival
100%
80%

92.6%
74.8%

60%
30.3%

40%

27.0%

20%
0%
Localized Regional

Distant Unknown

Figure 1. Percent of cases by stage and five-year relative survival in
ovarian cancer patients by stage at diagnosis. Figure adapted from
Surveillance, Epidemiology, and End Results (SEER) Program
(www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research
Data, 9 Registries, Nov 2020 Sub (1975-2018) - Linked To County Attributes Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National
Cancer Institute, DCCPS, Surveillance Research Program, released April
2021, based on the November 2020 submission. Cancer Stat Facts: Ovarian
Cancer. SEER Research Data 2011-2017.
https://seer.cancer.gov/data/citation.html. Published 2022. Accessed March 8,
2022.1
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Treatment strategies in ovarian cancer
Once diagnosed, the backbone of treatment for advanced (stage 3-4) ovarian
cancer includes tumor reductive surgery aimed at removing all visible disease,
followed by platinum-based cytotoxic chemotherapy.9 Traditionally, the approach is
to use what is called doublet therapy, where treatment is initiated with a combination
of carboplatin and paclitaxel; these work by disrupting DNA cross-linkages and
altering microtubule stability, respectively.10 The therapeutic efficacy of this up-front
doublet regimen in treating advanced stage ovarian cancer is well established.10,11
However, despite initial response rates for first-line treatment ranging from 70-80%,
the majority of these women with advanced stage disease will subsequently relapse
or progress and require further treatment.12,13 Since the mid-1990’s, the treatment
options for ovarian cancer were simple since there were only a handful of therapeutic
agents to choose from.12 A turning point in therapeutic advances occurred in 2014
when several new classes of drugs, including the targeted agent called
bevacizumab, gained approval from the U.S. Food and Drug Administration (FDA).14
Bevacizumab is a humanized monoclonal antibody against the vascular
endothelial growth factor (VEGF) receptor present on endothelial and other cells.14,15
This anti-VEGF antibody (AVA) therapy targets one of the established hallmarks of
cancer: angiogenesis, or the capability of a tumor to develop new blood vessels.16,17
Above and beyond angiogenesis, VEGF is an attractive target for development as a
therapeutic strategy because of the relationship that the VEGF receptor has with
many well-known metabolic pathways that ultimately impact cell survival, cell
migration, and cell proliferation in addition to angiogenesis as highlighted below in
Figure 2.18 Given the significant regulatory role that it plays, it is no surprise that
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tumors possess large reservoirs of VEGF and that targeting this with AVA therapy
is a rational approach to anti-cancer therapy.18

Figure 2. Diagram of the numerous metabolic pathways mediated by the
VEGF receptor family. Effects of activation of the VEGF receptor include
regulation of pathways involved in cell survival, cell migration, cell
proliferation, and vascular permeability via the AKT/PKB, PI3K, MAPK and
PIP2 pathways, respectively, before the downstream effect of increased
angiogenesis. Figure reprinted with permission. Mahdi A, Darvishi B,
Majidzadeh‐A K, Salehi M, and Farahmand L. Challenges facing
antiangiogenesis therapy: The significant role of hypoxia‐inducible factor and
MET in development of resistance to anti‐vascular endothelial growth factor‐
targeted

therapies.

J

Cell

Physiol.

2019;234(5):5655-5663.

DOI:

10.1002/jcp.27414.18
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AVA therapy and the impact of hypoxia
Due to the abnormal vasculature inherent in solid tumors during malignant
growth, it has been well described that tumors possess hypoxic and even anoxic
regions (Figure 3) as a result of the imbalance between tumor proliferation rate and
oxygen content.2 The increased metabolic activity in proliferative tumors means that
the oxygen demand exceeds oxygen supply, therefore leading to this hypoxia.19
Compared to physiologic oxygen tensions within the parenchyma of normal organs
of 20-40%, the oxygen tensions within solid tumors is much lower, estimated to be
1-2%.20 After the additional hypoxic stress imposed by treatment with AVA therapy,
these oxygen tension levels are estimated to be even lower than 1%.20,21
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Figure 3. Hypoxia within solid tumors. Tumors possess areas of both
hypoxia and necrosis due to the disorganized vasculature leading to an
imbalance of available oxygen and nutrient demands and blood supply. Figure
reprinted with permission. All Frontiers articles from July 2012 onwards are
published with open access under the CC-BY Creative Commons attribution
license (the current version is CC-BY, version 4.0). The content is free to
download, distribute, and adapt for commercial or non-commercial purposes,
given appropriate attribution to the original article. Al Tameemi W, Dale TP, AlJumaily RMK, and Forsyth NR. Hypoxia-Modified Cancer Cell Metabolism.
Frontiers in cell and developmental biology. 2019;7:4-4.2

While hypoxia in a normal cell would lead to cell death, hypoxia in tumor cells
can induce a selective pressure that breeds resilient cells (Figure 3). This leads to
the survival of subpopulations of cells that possess genomic changes enabling them
to adapt to the hypoxic stress and maintain adequate nutrition despite the hostile
tumor microenvironment (TME).2 As described by Hanahan et al. and others, during
tumor growth and progression there is an “angiogenic switch” that becomes
activated making the normally quiescent process of neovascularization become
constitutively activated as a way to thrive despite the lack of oxygen.20,22 This leads
to continual expansion of new vessels to help meet the high oxygen demand and
therefore support ongoing tumor growth and development.22 A number of regulators
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of this “switch” have been identified, but targeting VEGF and its receptors has proven
most promising because they serve as a rate-limiting factor of the angiogenic
function of the tumor cells.22 Therefore, AVA treatment represents not only one of
the first targeted agents against angiogenesis but also is the first effective
biologically targeted therapy within the realm of ovarian cancer treatment,
specifically.14
Targeting angiogenesis with AVA therapy further increases the relative
hypoxia in the TME, starving the tumor of important nutrients for growth and inducing
an even greater dependence on hypoxia adapatations.17,23 Adding to its efficacy as
a targeted therapy, AVA has been found to be potentiated by paclitaxel’s
antiangiogenic properties of inhibiting endothelial cell proliferation and migration,
and AVA is also known to be synergistic with carboplatin because carboplatin
induces VEGF expression in the TME.24 Due to these combined mechanisms, AVA
treatment is added to traditional chemotherapy at the time of first recurrence. In this
setting, AVA has consistently demonstrated modest improvements in the time to
disease recurrence, also known as progression free survival (PFS), across five
principal phase III randomized trials of women with advanced stage ovarian
cancer.24-27 Two of these trials, titled AURELIA and OCEANS, are represented in
Figure 4 below and demonstrate that in patients with platinum-resistant and
platinum-sensitive disease, there is a 52% and 55% reduction in the risk of
progression or death with a PFS benefit of 3.3 and 3.7 months, respectively when
AVA therapy (bevacizumab) is combined with traditional chemotherapy.25,27
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Figure 4. Kaplan-Meier curves for two large randomized controlled trials
investigating the efficacy of AVA (bevacizumab) in combination with
chemotherapy treatment. (Left) Survival curve demonstrating the progression
free survival benefit from bevacizumab of 3.3 months (HR 0.48, p < 0.001) from
a phase III trial called AURELIA27 which evaluated the combination of
bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer.
CT, chemotherapy; Bev, bevacizumab, HR, hazard ratio. (Right) Survival curve
representing the progression free survival benefit from bevacizumab of 3.7
months (HR 0.45, p < 0.0001) from a phase III trial called OCEANS 25 which
evaluated the combination of bevacizumab and chemotherapy for platinumsensitive recurrent ovarian cancer. GC, gemcitabine + carboplatin; BV,
bevacizumab; PL, placebo, HR, hazard ratio. Figures reprinted with permission
from Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G,
Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A,
Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with
chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA
open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308 and
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak
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MA, Jing YI, Nycum LR. OCEANS: A Randomized, Double-Blind, PlaceboControlled Phase III Trial of Chemotherapy With or Without Bevacizumab in
Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary
Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2012;30(17):2039-2045.
These articles are published with open access under the CC-BY Creative
Commons attribution license (the current version is CC-BY, version 4.0). The
content is free to download, distribute, and adapt for commercial or noncommercial purposes, given appropriate attribution to the original article.

Beyond this demonstrated efficacy in the relapsed or recurrent setting, there
have been additional trials indicating a similar PFS benefit when given as first line
treatment, known as the “up-front” setting (i.e. GOG-218 and ICON7 trials).26,28
These findings therefore led to AVA therapy with bevacizumab gaining approval by
the FDA for use in both the up-front and recurrent disease settings.14 Practically
speaking, this means that nearly all patients with advanced ovarian cancer will be
treated with AVA therapy at some point in their care.
Adaptive resistance to AVA therapy in ovarian cancer and the role of
glutamine
Unfortunately, despite the modest improvement in PFS as outlined above, a
more durable overall survival (OS) benefit from AVA therapy has yet to be
recognized in any setting.24,29 This is likely due to the emergence of a rapid adaptive
resistance within several months of initiating AVA treatment, which thus prevents
the achievement of any OS benefit.29 Additionally, the lack of OS benefit may also
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be due to the intrinsic limitations of OS as a metric itself. While OS is one of the most
frequently utilized endpoints used in drug development, it is not necessarily the most
reliable method of determining therapeutic efficacy. A more accurate assessment of
drug responses in recurrent disease is the interval of time that patient survives after
progression of disease, known as survival post-progression (SPP).30 The longer
SPP that a patient has, the less reliable OS is as a metric. Historically, FDA approval
of new therapeutic drugs is based on OS, however approvals are increasingly based
on PFS or overall response rate (ORR) because of these limitations in OS.
However, despite the limitations of OS, drug resistance in recurrent ovarian
cancer translates to the fact that it is almost never cured, with the majority of women
spending the duration of their time with relapsed disease (i.e. the SPP interval)
switching from one drug to another until the disease again progresses without any
further options to treat it. This therefore underscores the importance of deciphering
the mechanisms by which tumors develop an adaptive resistance to AVA therapy
and a pressing need for more effective treatment strategies to overcome AVA
resistance.
In both preclinical and clinical models, blocking the VEGF signaling axis
pictured above in Figure 2 results in a metabolic rewiring as a means of maintaining
energy supply for tumor growth.15 One of the adaptations to the hypoxic environment
induced by AVA therapy is an upregulation of the expression of a family of hypoxia
inducible factors (HIF), namely HIF-1α and HIF-2α, which in turn, can lead to an
upregulation of compensatory cellular processes that circumvent the inhibition of
angiogenesis.18 These include alternate or parallel pathways of angiogenesis, as
well as pathways involved in catabolism and cellular proliferation, erythropoiesis,
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apoptosis.31 It is therefore plausible that targeting neovascularization with AVA and
also simultaneously targeting the associated hypoxic adaptations driven by HIF-1α
could yield improved therapeutic results and potentiate the duration of effect of AVA
therapy.23
Of the known metabolic adaptations that occur in AVA resistance, glucose
metabolism has been a central theme of investigation following the discovery of the
now well-described Warburg effect, whereby tumors rely on alternative respiration
instead of engaging in mitochondrial oxidative phosphorylation to maintain energy
for anaplerosis.32,33

But beyond glucose metabolism, there has been growing

emphasis on the role of alternate nutrients, such as glutamine, which helps to sustain
a high level of proliferation even under conditions of hypoxia and glucose
deprivation.34,35 In fact, some cancer cell types demonstrate a “glutamine
dependence” or “glutamine addiction” where they fail to grow or proliferate in the
absence of glutamine.36 In preclinical models when tumors are under the hypoxic
stress imposed by AVA, part of the metabolic rewiring observed in the TME is an
increase in glutamine metabolism (glutaminolysis) as a means to circumvent the
reduced capacity for aerobic respiration.23 This then, represents a possible
vulnerability that could be targeted in ovarian cancer.
Glutaminolysis and its significance in ovarian cancer
As demonstrated in Figure 5 below, the downstream effects of glutaminolysis
are multifaceted. Glutamine can be utilized as a source of carbon and nitrogen to
support biosynthesis and cellular hemostasis but can also serve as a building block
for glutathione, a scavenger for reactive oxygen species.34,37 Because of this
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plurality of glutamine utilization, it is understandable that glutamine dependence has
been linked to the level of invasiveness of cancer cells in vitro and that glutaminolysis
correlates clinically with poor survival.38 The ultimate utilization of glutamine requires
its catabolism by the enzyme glutaminase (GLS) into the active metabolite,
glutamate, which is subsequently converted to α-ketoglutarate for its use in the
Kreb’s cycle (Figure 5).39

Figure 5. Metabolic and biosynthetic fates of glutamine. Figure
reprinted with permission from Altman BJ, Stine ZE, and Dang CV. From
Krebs to clinic: glutamine metabolism to cancer therapy. Nature reviews
Cancer. 2016;16(10):619-634.34
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GLS has two isoforms, GLS (also called GLS1) and GLS2, however GLS2 is
not widely expressed in tumors and will not be discussed here further.35,40 GLS has
increased activity during metabolic reprogramming of cancer cells after exposure to
stressors such as AVA therapy, and its expression has been correlated with a
multitude of oncogenic pathways including HIF-1α, cMYC, EGFR, RAS/MAPK, and
PI3K/AKT/mTOR.34,41 Importantly, a high expression of GLS has been reported in
many solid tumors and it is correlated with poor disease outcomes. Specifically
within ovarian cancer, the median OS was almost two years shorter for patients with
a high versus a low expression level of GLS (35.9 vs 58.6 months, respectively;
Figure 6).35 Therefore, GLS inhibitor (GLSi) therapy is a potentially valuable
therapeutic strategy.
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Figure 6. Kaplan-Meier curve of disease-specific survival as it relates to
GLS1 expression. In a cohort of 129 patients with HGSC, median survival
was 35.9 vs 58.6 months for patients with a high vs. a low GLS1 expression
level, respectively (p < 0.001). Figure reprinted with permission from
www.kmplot.com that is published with open access under the CC-BY
Creative Commons attribution license; the content is free to download and
adapt given appropriate attribution to the original article: Gyorffy B, Lánczky
A, Szállási Z. Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray data from
1287 patients. Endocr Relat Cancer. 2012;19(2):197-208.3

Glutaminase inhibitor (GLSi) targeted therapy
Several GLS inhibitors have been commercially developed, but CB-839
(Telaglenastat) is the agent most robustly investigated.42 CB-839 has been studied
in over 10 clinical trials evaluating its efficacy in solid tumors as both single agent
therapy and also in combination with traditional chemotherapeutics.43-55 Targeting
GLS with GLSi therapy in vitro in ovarian cancer cell lines has demonstrated a
synergistic effect with standard chemotherapy.56 Additionally, and perhaps more
importantly, GLSi has been shown to re-sensitize cell lines that are resistant to both
platinum and taxane chemotherapy.57 Despite this exciting preclinical work, the
potential for GLSi in ovarian cancer has yet to be realized. While there are multiple
active clinical trials investigating the use of GLSi in ovarian cancer treatment,44,54 the
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use of a GLSi in the context of AVA-resistant ovarian cancer has not been
investigated.
Given the nearly ubiquitous use of AVA treatment in ovarian cancer and the
high rates of adaptive resistance that develop in response to therapy, there is an
ever-expanding patient population with AVA-resistant disease that have limited
treatment options available. It is therefore imperative that the relationship between
glutamine metabolism and AVA-resistance be more well defined in pursuing this as
a therapeutic strategy in the clinical realm. The purpose of this work is to explore the
metabolic adaptations that occur in adaptive resistance to AVA therapy and to
determine whether these changes could render AVA-resistant ovarian cancers
susceptible to treatment with GLSi targeted therapy.
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HYPOTHESIS AND SPECIFIC AIMS
Hypothesis: Hypoxia-mediated glutamine dependence in AVA-resistant ovarian
cancer will make it susceptible to GLS inhibitor therapy.
Figure 7, on the next page, demonstrates a graphical representation of the
conceptual framework of this hypothesis.
Specific Aim 1: To test the in vitro effects of hypoxia on glutamine metabolism.
Specific Aim 2: To test the in vitro effects of glutaminase inhibition on ovarian
cancer cells and endothelial cells under hypoxic conditions.
Specific Aim 3: To test the biological relevance of glutaminase inhibition in wellcharacterized mouse models of adaptive resistance to AVA therapy in ovarian
cancer.
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Figure 7. Working model of the central hypothesis. Exposure to bevacizumab
(anti-VEGF monoclonal antibody, AVA) creates a hypoxic TME leading to an
increased expression of hypoxia inducible factor 1 alpha (HIF-1α). This hypoxic
trigger then creates a metabolic shift toward dependence on glutamine catabolism
for tumor growth and progression. The hypoxia-induced metabolic adaptation
represents a potential vulnerability that could be exploited by inhibiting the GLS
enzyme with a GLS inhibitor (GLSi) in combination with AVA treatment such as
bevacizumab.

Figure

Created

with

BioRender.com.

TME,

tumor

microenvironment; α KG, alpha ketoglutarate; HIF-1α, hypoxia inducible factor-1
alpha.
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MATERIALS AND METHODS
Cell lines and culture conditions
The human ovarian cancer cell lines SKOV3ipluc (RRID: CVCL_0C84),
OVCAR5 (RRID: CVCL_1628), and OVCAR8 (RRID: CVCL_1629) were obtained
from the ATCC and The University of Texas MD Anderson Cancer Center
Cytogenetics and Cell Authentication Core. The immortalized human vascular
endothelial cell line RF24 (RRID: CVCL_AX74) was obtained from Dr. Lee Ellis (MD
Anderson Cancer Center). SKOV3ipluc and OVCAR8 cells were cultured in RPMI
1640 medium (HyClone) supplemented with 10% fetal bovine serum (Sigma-Aldrich)
and 1% gentamycin. OVCAR5 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and 1% gentamycin. RF24 cells
were cultured in minimum essential medium supplemented with 10% fetal bovine
serum, sodium pyruvate, non-essential amino acids, and 1% gentamycin. All cells
were cultured at 37°C with 5% CO2 and ambient atmospheric O2 unless performing
a hypoxia experiment, in which case they were cultured with 1% O2 as indicated. All
cell lines were authenticated by the Cytogenetics and Cell Authentication Core using
short tandem repeat fingerprinting and were tested for mycoplasma contamination
using polymerase chain reaction. Cells were used within 20 passages after thawing
for in vitro experiments and 10 passages after thawing for in vivo experiments.
Cell viability assay
To evaluate the cytotoxic effects of GLSi and bevacizumab as monotherapy
and in combination on cell viability, ovarian cancer cells (SKOV3ip1, OVCAR5, and
OVCAR8) were seeded in a 96-well plate at a density of 3,000 cells per well in 100µL total volume in quadruplicates. Cells were incubated for 24 hours, and after
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demonstration of adequate attachment, the culture medium was removed and
replaced with a medium containing serial dilutions of GLSi and bevacizumab. The
cells were then incubated for 24, 48, or 72 hours depending on the experimental
oxygen conditions. Following incubation, the cells were treated with a 0.05% MTT
solution for 2-4 hours. The supernatant was then gently removed, and the MTT
formazan was dissolved in 100 µL of dimethyl sulfoxide. The absorbance was
subsequently read at 570 nm using a BioTek uQuant microplate spectrophotometer.
All experiments were performed in triplicate. Dose-response curves were plotted
using Prism software (version 8.0.0; GraphPad Software).
Western blotting
Extraction of total protein cell lysates was performed using modified RIPA
buffer with protease and phosphatase inhibitors. BCA Protein Assay Reagent
(Thermo Fisher Scientific) was then used to measure protein concentrations. Protein
expression for each lysate was subsequently detected via Western blotting of a
sodium dodecyl sulfate-polyacrylamide gel electrophoresis separation gel using a
primary antibody against GLS (cat. #12855-1-AP; Proteintech). The antibody was
incubated overnight at 4°C and then incubated with corresponding horseradish
peroxidase-linked whole secondary antibodies. A chemiluminescence assay using
a Western Lightning PLUS ECL Kit (PerkinElmer) was performed to expose the
membranes and protein bands were quantified using densitometry with ImageJ
software (National Institutes of Health). β-actin was used as a sample loading control
for all reads.
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Quantitative RT-PCR (qRT-PCR)
Relative levels of mRNA expression of GLS were detected using the qRTPCR method as described before.38 Briefly, each qRT-PCR was carried out with 1
μg of RNA isolated from cells using RNeasy Mini Kits (Qiagen, CA) and reverse
transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems Inc.) according to the manufacturer’s protocol. The cDNA synthesized
was then used as a template in the qRT-PCR using the specific GLS TaqMan Gene
expression probes (Hs0104020_m1, ThermoFisher). Quantitative RT-PCR was
performed on a 7500 Real-Time PCR System (Applied Biosystems, Inc.). The 18s
rRNA was used as endogenous control, and relative mRNA expression was
calculated using 2−ΔΔCTmethod.58
GLS gene silencing by small interfering RNA
Small interfering RNA (siRNA) targeted to GLS was purchased from SigmaAldrich. In vitro transient transfection was performed as described previously.59
Briefly, the cells were transfected with a GLS1-specific or scrambled (control) siRNA
using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). siRNA with a
nonspecific function that shared no sequence homology with any known mRNA in a
BLAST search was used to control the target siRNA (Mission siRNA Universal
Negative Control#1, Sigma). At selected time intervals, cells were harvested to
measure mRNA levels of GLS1 using qRT-PCR.
In vivo models of ovarian cancer
All animal protocols were approved by the MD Anderson Institutional Animal
Care and Use Committee. All animal experiments were performed with 6- to 8-weekPage | 20

old female athymic nude mice (NCr-nude) obtained from Taconic Biosciences. The
mice were housed five per cage under pathogen-free conditions at a constant
temperature and humidity. All mice were fed a regular diet and water ad libitum
according to the guidelines of the American Association for Laboratory Animal
Science and the U.S. Public Health Service Policy on Humane Care and Use of
Laboratory Animals. Investigators sacrificed the mice via carbon dioxide euthanasia
followed by cervical dislocation once the mice were moribund.
To establish xenograft models for all mouse experiments, luciferase-labeled
SKOV3ip1 ovarian cancer cells were cultured to 70-90% confluence and then
trypsinized, washed twice with phosphate-buffered saline, and resuspended in icecold Hank’s Balanced Salt Solution (cat. #21-021-CV; Cellgro). The mice were then
inoculated with 1 x 106 SKOV3ip1 cells via intraperitoneal injection to the right side
of the abdomen. Tumor establishment was subsequently confirmed after injection of
200 µL of 14.3 mg/mL luciferin (cat. #LUCK-1G; GoldBio) using a Xenogen IVIS in
vivo imaging system. Mice without tumor uptake were removed from the experiment.
Following confirmation of disease burden, all mice in the therapeutic experiment
were randomly assigned to the following treatment groups: vehicle control,
bevacizumab (AVA; 6.25 mg/kg, intraperitoneally, twice a week), GLSi (IACS012031, 200 mg/kg given orally twice daily, five days a week), or a combination of
the two at these doses (n = 15 for all groups).
In the AVA-resistance model, twice-weekly treatment with bevacizumab
(AVA) was initiated upon confirmation of tumor uptake. Tumor burden was
subsequently assessed weekly via IVIS imaging (Xenogen), and the mice were
placed in two groups: AVA-sensitive and AVA-resistant. Sensitivity to AVA therapy
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was defined as a decrease or plateau in the relative intensity of bioluminescent
signaling over three weeks of treatment. The AVA-sensitive mice were sacrificed
approximately one week later to confirm that they truly had sensitive phenotypes.
Resistance to AVA therapy was defined as an initial decrease then steady increase
in the relative intensity of bioluminescent signaling. The resistant group was then
separated into two groups: control (AVA plus vehicle control given via oral gavage
twice a day, n = 20) and AVA treatment (AVA plus GLSi given via oral gavage twice
a day, n = 25). The treatment in both groups continued until each mouse became
moribund at which point, they were sacrificed. The mice were monitored daily for
adverse effects of treatment, and their body weights were measured weekly.
Survival time was calculated for each mouse as the number of days from the date
of inoculation of SKOV3ip1 cells to the date of euthanasia.
Mouse tumor weights, nodule numbers, distribution of metastasis, and
presence of ascites were recorded at the time of gross necropsy. All tumor tissues
were dissected, and samples were snap-frozen for later protein or RNA analysis
(e.g., DESI-MS, LC-MS), fixed in formalin for paraffin embedding, or snap-frozen in
optimal cutting temperature compound (Mercedes Scientific) for frozen slide
preparation.
Bevacizumab was obtained from MD Anderson pharmacy. The glutaminase
inhibitor, IACS-012031, was obtained from the MD Anderson Institute for Applied
Cancer Science and reconstituted in 25% aqueous 2-hydroxypropyl-β-cyclodextrin
(cat. #H107-100G; Sigma-Aldrich) in phosphate-buffered saline at a dose of 25
mg/mL. This was administered via oral gavage as above.
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IHC staining
All tumor samples subjected to IHC staining were collected from the in vivo
experiment. Formalin-fixed, paraffin-embedded tumor sections were used for
staining for anti-Ki67 (1:100, cat #RB-9043-PI; NeoMarkers). Paraffin slides were
prepared via deparaffinization and antigen retrieval, whereas frozen slides were
prepared via cold acetone fixation. This was followed by endogenous peroxide
blocking with 3% hydrogen peroxide and a protein block with 4% fish gelatin. All
samples were incubated with a primary antibody diluted in 4% fish gelatin overnight
and then incubated with either a peroxidase-conjugated goat anti-rabbit or antimouse secondary antibody for one hour at room temperature.
Frozen slides were used for staining for CD31 (1:800, cat. #53370; BD
Pharmingen) and CA9 (1:100, cat# NB100-417SS; Novus Biologicals) using goat
anti-rat and goat anti-rabbit horseradish peroxidase-linked secondary antibodies,
respectively (1:250, cat. #112-035-167; Jackson ImmunoResearch). Frozen slides
were prepared by first fixing slides in cold acetone for 10 minutes and then washing
them in phosphate-buffered saline and blocking with endogenous peroxidase and
3% H2O2 in methanol. All samples were incubated with a primary antibody diluted in
protein block (5% normal horse serum and 1% normal goat serum in phosphatebuffered saline) overnight at 4°C. The slides were incubated with a secondary
antibody for one hour and subsequently incubated with DAB (Invitrogen, Cat.
#750118). Microscopic assessment of DAB staining was performed for all slides to
monitor appropriate staining density. The slides were counterstained with
hematoxylin (Gill 3). Quantification of IHC staining was performed by randomly
selecting five fields at 200x magnification per slide and manually counting stained
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nuclei in each field. Mean cell count and standard deviation (SD) was calculated,
and treatment groups were compared using the Student t-test.
Polar metabolite extraction from tissue
The protocol was modified from Zhou et al, 2020.60 To minimize metabolite
degradation, tumor tissue samples were kept on dry ice throughout the LC-MS
experiment. Briefly, 30-66 mg of each tissue sample was quickly weighed in a
homogenizer tube previously filled with beads. A prechilled methanol/water (1:1, v/v)
solution was added to the tube based on the weight of the measured tissue (5 mL
per 1 g of tissue, or 125 µL per 25 mg of tissue). The samples were then
homogenized using a Precellys homogenizer (Bertin Instruments) at 4°C and 6,500
rpm using two cycles of 25 seconds with 30-second intervals. Afterward, 100 µL of
the tissue homogenate was transferred to a fresh tube, and 500 µL of
methanol/water (1:1, v/v) solution and 500 µL of chloroform were added to the
samples and they were vortexed for two minutes at 4°C and centrifuged at 16,000g
for 10 minutes at 4°C. A total of 500 µL of polar metabolite extract was then dried in
a vacuum evaporator. The dried metabolites were reconstituted in 200 µL of
methanol/water (1:1, v/v) solution, sonicated for 10 minutes, and filtered through an
Agilent 0.2-µm Econofilter. The filtrate was then transferred into LC vials for analysis.
LC-MS protocol and data analysis
A 10 µL tumor sample prepared in the manner outlined above was injected
for analysis into an Agilent 6520 Q-TOF LC/MS machine with an ACQUITY UPLC
BEH C18 Column (130 Å, 1.7 µm, 2.1 mm x 150 mm) coupled with VanGuard PreColumns and an XBridge BEH Amide XP Column (130 Å, 2.5 µm, 4.6 mm x 150
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mm) coupled with an XBridge BEH Amide XP VanGuard Cartridge (130 Å, 2.5 µm,
2.1 mm x 5 mm). The column compartment was set at 40°C, and the analysis was
performed in both positive and negative modes. One hundred microliters of sample
filtrate was transferred to LC vials, and 10 µL of each filtered sample was pooled to
form the quality control samples. For analysis of the C18 column, mobile phase A
consisted of water with 0.1% formic acid, whereas mobile phase B contained
acetonitrile in 0.1% formic acid. The gradient method using the C18 column was as
follows: 0 minutes: 1% B; 1 minute: 1% B; 8 minutes: 99% B; 13 minutes: 85% B;
13.1 minutes: 1% B; 16 minutes: 1% B. For analysis with the HILIC column, the
mobile phase A was 10 mM ammonium formate in water with 0.1% formic acid,
whereas mobile phase B contained 10 mM ammonium formate in acetonitrile with
0.1% formic acid. The gradient method using the HILIC column was as follows: 0
minutes: 99% B; 11.8 minutes: 20% B; 12.5 minutes: 99% B; 14.7 minutes: 99% B.
The metabolite peaks were extracted for the analysis using Agilent MassHunter
Profinder software based on our in-house library of metabolites. Any metabolites
whose relative SD was greater than 30% in the QC measurements were excluded
from further analysis. The metabolite peak areas in the spectrum were normalized
according to the weight of the tissue. Other downstream analyses were performed
using MetaboAnalyst software version 5.0 and data were then presented with the
aid of Graphpad prism version 8.0.0.
DESI-MS Imaging and SAM Analysis
Tumor tissues were flash-frozen and stored at -80°C prior to analysis. Frozen
tissues were sectioned at 12 μm thickness, thaw-mounted onto glass slides, and
immediately analyzed using a Q Exactive Focus or Q Exactive HF Orbitrap mass
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spectrometer (Thermo Fisher Scientific) coupled to a 2D OmniSpray stage (Prosolia
Inc.) and a laboratory-built DESI sprayer. DESI-MS imaging was performed in the
negative ion mode at a spatial resolution of 200 μm using a mass resolving power
of 70,000 (m/z 200) and an instrument method optimized for enhanced detection of
small metabolite species from m/z 80-500. A histologically compatible solvent
system comprised of methanol:acetone 4:1 (v/v) was used as the DESI spray
solvent, at a flow rate of 5.0 μL/min. DESI-MS ion images were assembled and
visualized using Firefly (Prosolia, Inc.) and BioMap (Novartis) software. Ions of
interest were tentatively identified using high mass accuracy measurements and
tandem mass spectrometry experiments.
After DESI-MS imaging, the analyzed tissue sections were stained with
hematoxylin and eosin and regions of tumor, stroma, and necrosis were annotated
by D.G. within each sample. Mass spectra were extracted from pixels corresponding
to tumor regions within the DESI-MS dataset using MSiReader software. The
resulting ion intensity matrix was processed by binning each m/z value to the nearest
thousandth and removing peaks that were present in less than 20% of the extracted
pixels. The extracted DESI-MS data was analyzed using significance analysis of
microarrays (SAM), a modified significance test to identify statistically significant
alterations in relative abundance for specific mass-to-charge (m/z) values.61
Multiclass SAM was performed in R using the “samr” package to identify features
with significantly altered abundance among treatment groups. A false discovery rate
(FDR) of 5% was applied to identify m/z values with significant differences in relative
abundance among treatment groups. Ion intensities for selected metabolites of
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interest were plotted in GraphPad Prism (version 9.3.0) and subjected to one-way
ANOVA with Tukey’s post-hoc test for pairwise comparisons.
Hyperpolarized 13C-pyruvate sample preparation
A solution of 20 µL of 13C pyruvic acid (ISOTEC; Sigma-Aldrich), 15 mM OX63
trityl radical (GE Healthcare), and 1.5 mM gadolinium chelate (ProHance) was
polarized at 3.35 T and 1.4 K using dynamic nuclear polarization (HyperSense;
Oxford Instruments) for one hour. A frozen

13C-pyruvate

sample was rapidly

dissolved in 4 mL of superheated alkaline buffer containing 100 mg/L EDTA, 40 mM
NaOH, 40 mM TRIS buffer, and 30 mM NaCl. The final concentration of pyruvate to
be injected into the mouse tail vein was 80 mM, with a physiologic pH of about 7.4.
In total, 200 µL of hyperpolarized pyruvate was injected into mice using a tail vein
catheter for 8-10 seconds.
Animal handling during magnetic resonance imaging experiments
For magnetic resonance imaging (MRI) experiments, a 7T Bruker BioSpin
MRI scanner (horizontal bore) was used. Mice were anesthetized using isoflurane
in an anesthesia chamber with scavenging. The animals were fixed in a holder
specially designed for mice and placed in the MRI coil equipped with a nose cone
for inhaled analgesia. A respiration monitoring pad and body temperaturemaintaining heated pad were used during the MRI experiments.
T2-weighted proton MRI
Conventional anatomic magnetic resonance images of mice were acquired
using multislice T2-weighted rapid acquisition with a relaxation enhancement
sequence. Images with different views, including axial, coronal, and sagittal views,
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were acquired to identify tumors and regions of interest in the flanks of the mice. The
imaging parameters for the T2-weighted scans were an echo time of 15 milliseconds,
repetition time of 2.5 seconds, 4-cm field of view, 256 µm × 256 µm in-plane
resolution, 10 slices with thicknesses of one mm, and four image averages.
In vivo 13C magnetic resonance spectroscopy
A series of slab-selective

13C

spectra with a slab thickness of 8 mm were

acquired right after injection of mice with hyperpolarized pyruvate using an SP Flash
sequence. The intraperitoneal tumor locations and similar sizes of the tumors in the
experimental mice used in this study increased the precision of slab placement
through most of the ovarian tumors and limited the contribution of nonmalignant
signals consistently throughout the experiments. A total of 90 transients were
acquired using a delay time between each transient of two seconds (total time, three
minutes). For each transient, a 15° flip angle excitation Gaussian pulse and 2,048
data points were used. A small 8M 13C urea phantom injected with gadolinium-DPTA
was used in each mouse experiment for chemical shift referencing. Experimental
data were processed on the MATLAB programming language (The MathWorks, Inc.)
and TopSpin (Bruker BioSpin) platforms. Phase correction and 10- to 15-Hz line
broadening were introduced to each individual spectrum. The areas under the
spectral peaks within the frequency range for pyruvate and lactate were integrated
over the entire array. The lactate-to-pyruvate metabolic flux ratios (lactate/pyruvate)
were estimated by calculating the individual integration of lactate and pyruvate
spectral signals between treatment groups and comparing the change in signal over
time.

Page | 28

Statistical analysis
Differences between groups were evaluated using the Student t-test or MannWhitney U test according to data distribution and variance homogeneity. One-way
differences between two groups were evaluated using the Student t-test or MannWhitney U test according to data distribution and variance homogeneity, whereas
one-way analysis of variance was used for multiple group comparison. For survival
experiments, Kaplan-Meier analysis and a log-rank test were performed to explain
differences in survival. All statistical analyses were conducted using Prism software
(version 8.0.0). The p values were two-tailed and values less than 0.05 were
considered significant. All results were presented as means (± SEM or SD).
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RESULTS
Treatment with, and adaptive resistance to, AVA therapy induces alterations
in glutamine metabolism in vitro
Given the known inherent hypoxia in the TME and the added hypoxic stress imposed
by AVA therapy,19,20 we set out to understand the impact of hypoxia extremes on
glutamine metabolism. To do so, we first evaluated the in vitro GLS expression in
the ovarian cancer cell line OVCAR8 and endothelial cancer cell line RF24 when
cultured in hypoxic conditions at 1% O2 versus normal atmospheric oxygen (i.e. 20%
O2). We did this in concert with measuring the HIF-1α expression level. Our results
indicate that GLS and HIF-1α expression in both cell lines was higher under hypoxic
rather than under normoxic conditions (Figure 8 A, B).
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Figure 8. Metabolic alterations in hypoxia and resulting from AVA
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therapy. RF24 and OVCAR8 cells were cultured in normoxia (N) or hypoxia

(H) for 12 and 24 hours. GLS and HIF-1α protein (A) and GLS mRNA (B)
expression levels in both cell lines were measured. Error bars indicate
standard deviation (SD), ***p < 0.001.
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To evaluate the downstream metabolic effects of an increased GLS
expression in hypoxia, we performed an in vivo investigation using an orthotopic
SKOV3ip1 model of ovarian cancer with adaptive resistance to AVA therapy with
bevacizumab (Figure 9). In this experiment, 60 nude mice inoculated with luciferase
labeled cells received either a vehicle control (200 uL) or AVA therapy (200 uL, 6.25
mg/kg) via intraperitoneal (i.p) injection twice weekly until resistance to AVA therapy
emerged. The resistance rate was 87% (n = 52).

Figure 9. In vivo model of adaptive resistance to AVA therapy. Female
nude mice were inoculated with 1x106 luciferase labeled SKOV3ip1 ovarian
cancer cells. After confirming tumor uptake, mice were randomized to receive
either a vehicle control or AVA therapy with bevacizumab (6.25 mg/kg). Serial
imaging was performed on control mice to assess tumor growth and on AVAtreated mice to monitor for resistance to therapy. Tumors were harvested
once resistance was observed.
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All mice underwent weekly bioluminescence imaging with radiance scores
tracked over time for the AVA-treated mice in order to stratify them based on
sensitivity or resistance to AVA therapy as outlined in the Materials and Methods
(Figure 10).
Control

Resistant Sensitive

Figure 10. Adaptive resistance to AVA therapy. Images of nude mice obtained via
an in vivo imaging system (IVIS) approximately six weeks after inoculation with 1x10 6
SKOV3ip1 cells. Mice received either a vehicle control or bevacizumab (6.25 mg/kg
twice weekly) and were imaged weekly until resistance emerged.

Tumors were harvested after the mice demonstrated resistance to AVA
treatment and markers of hypoxic stress using immunohistochemical (IHC) staining
were assessed. Compared with control tumors, all AVA-treated tumors had higher
levels of the hypoxia marker CA9 (p < 0.01, Figure 11A, B). As anticipated, the AVAsensitive tumors demonstrated a reduced vascular density with lower levels of the
endothelial cell marker CD31 compared with control tumors or with those that were
resistant to AVA treatment (p < 0.001, Figure 11 C, D).
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Figure 11. Effect of AVA resistance on markers of hypoxia and vascular cell
density. (A) IHC staining of frozen mouse ovarian tumors for the hypoxia marker
CA9 in control vs. AVA treated (bevacizumab 6.25 mg/kg i.p. twice weekly) tumors.
(B) Quantification of CA9 staining in control vs. AVA treated tumors per high power
field, error bars indicate standard deviation (SD), **p < 0.01. (C) IHC staining of
frozen mouse ovarian tumors for the endothelial cell marker CD31 in control vs. AVAsensitive or AVA-resistant tumors. (D) Quantification of vessel densities in control,
AVA-sensitive, and AVA-resistant tumor samples. Error bars indicate SD. ***p <
0.001 compared with the control group (Student t-test). Hpf, high power field; AVA,
anti-VEGF antibody (bevacizumab); AVA-sens, AVA-sensitive; AVA-resis, AVAresistant.
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After confirmation of the hypoxic stress in this orthotopic model of adaptive
resistance to AVA therapy, we set out to define the specific alterations in tumor
metabolism that occur in response to this stress. We first performed a quantitative
metabolic analysis of the AVA-treated tumor tissues from the above in vivo
experiment using liquid chromatography-mass spectrometry (LC-MS).

These

analyses revealed greater alterations in the purine synthesis pathway in AVAresistant samples than in AVA-sensitive and vehicle-treated control samples (Figure
12, FDR < 0.05). Specifically, the results indicated a greater abundance of
metabolites such as urate, xanthine, xanthosine, and 3-ureidopropionate in the AVAresistant group than in the control group (Figure 13 p < 0.05 and Figure 14, FDR <
0.05).
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Figure 12. Impact plot of adaptive resistance to AVA therapy in an
orthotopic murine model of ovarian cancer suggests alterations in
purine metabolism. Plot of metabolic pathway impact analysis results upon
LC-MS of control and AVA-resistant ovarian tumors from an orthotopic mouse
model with SKOV3ip1 cells showing that the purine and pyrimidine
metabolism in the groups differed markedly (FDR < 0.05). Data were
generated using a MetaboAnalyst plot made with Prism software.
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Figure 13. Metabolic alterations in the purine metabolism pathway after
adaptive resistance to AVA therapy in an orthotopic murine model of ovarian
cancer. Simplified diagram of the purine and pyrimidine metabolic pathways
showing the key metabolites involved in nucleotide metabolism. The inserted scatter
plots show significantly higher levels of downstream metabolites (urate, xanthine,
xanthosine, and 3-ureidopropionate) in the AVA-resistant group than in the control
group (p < 0.05). UMP, uridine monophosphate; OMP, orotidine 5'-monophosphate;
CMP, cytidine monophosphate; PRPP, phosphoribosyl pyrophosphate; GMP,
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guanosine monophosphate; XMP, xanthosine monophosphate; IMP, inosine
monophosphate; AMP, adenosine monophosphate.

Figure 14. Heat map of altered metabolic pathways in murine
ovarian cancer model with adaptive resistance to AVA therapy.
Heat map of altered metabolic pathways in control vs AVA-resistant
tumor tissues from the in vivo experiment outlined in Figure 9. Purine
and pyrimidine metabolism highlighted in blue on y axis. FDR < 0.05
with scale bar indicating log fold change |-2 to +2|.
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To further investigate the treatment-specific metabolic changes within the
heterogenous TME of this model, desorption electrospray ionization-mass
spectrometry (DESI-MS) imaging62,63 of the same tumor samples was subsequently
performed. Spatially resolved molecular information was selectively extracted from
the DESI-MS data obtained from tumor regions within each sample, excluding
adjacent stroma or necrotic tissue. Significance analysis microarray (SAM) identified
alterations in the relative abundance of a variety of molecular species when
comparing control to AVA-treated tumors, including multiple key intermediates in
amino acid metabolism, glycolysis, and purine synthesis (Figure 15, FDR < 0.05).
Higher relative abundances of xanthine and hypoxanthine were detected in the AVAresistant tumor tissue regions relative to control, in agreement with LC-MS
experiments (p < 0.01 and p < 0.03, respectively).
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Figure 15. Heat map of metabolic alterations assessed by DESI-MS in ovarian
cancer with adaptive resistance to AVA therapy.

Intensity heat map for

metabolites selected by SAM as significantly altered among control, AVA-resistant,
and AVA-sensitive tissues (FDR < 5%) identified by DESI- MS imaging. Features
were clustered using a Euclidean-distance formula according to the average signal
intensity of the corresponding m/z value measured from tumor-specific regions. The
color scale reflects z-score standard deviations from the mean relative abundance
measured for each ion. For fatty acid (FA) species, X:Y indicates the number of
carbons and double bonds, respectively.

Additionally, significant alterations in glutaminolysis metabolites were
identified with increased relative abundances of glutamate relative to glutamine in
AVA-resistant compared to AVA-sensitive tissues, but not when compared to control
(normalized ion abundance: 7.4 vs. 5.3 and 9.1, respectively; Figures 16 and 17, p
< 0.05). That is, the conversion of glutamine to glutamate in the AVA-resistant
tumors resembled that of the control whereas there was a reduced catabolism of
glutamine in the AVA-sensitive tumors. Similar trends were observed for fumarate
and glutathione, both of which are downstream metabolites of glutamate (data not
shown). Overall, our comprehensive mass spectral analyses of AVA-treated tumors
indicate a significant role of glutamine metabolism in these tumors, particularly in
AVA-resistance.
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Figure 16. Normalized ion abundance ratio of glutamate to glutamine in
AVA-resistance. Ion intensity ratio of glutamate to glutamine within tumor tissues
from an SKOV3ip1 ovarian cancer mouse model receiving no treatment (control)
vs. AVA-resistant (Resistant) or AVA-sensitive (Sensitive) tumors, as monitored
by in vitro imaging analysis. Statistical significance was determined by Tukey’s
HSD post hoc test, * p < 0.05.
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Figure 17. DESI-MS ion images of ovarian tumors with adaptive resistance to
AVA therapy. DESI-MS demonstrates an increase in glutaminolysis in AVA-resistant
tumors compared to control tumors, with an increased abundance of glutamate in all
AVA-resistant tumors compared to AVA-sensitive tumors but not compared to control
tumors. Normalized ion abundance: 7.4 vs. 5.3 and 9.1 for Resistant, Sensitive and
Control, respectively, p < 0.05. NL, normalization level.
Page | 42

Hypoxia induces GLS expression in a hypoxia-inducible factor-1 dependent
manner
In order to better understand the mechanisms by which GLS expression is
altered after exposure to AVA therapy, we evaluated the relationship of HIF-1α and
GLS expression. In many cancers, GLS expression has been documented to be
correlated with HIF-1α expression and level.20,64,65 To determine whether this is a
direct correlation, we analyzed ovarian cancer cells (OVCAR8) and endothelial cells
(RF24) that were transiently transfected with small interfering RNA (siRNA) targeting
HIF-1 or HIF-2 (Figure 18). We observed that the increased GLS expression seen
under hypoxic conditions (1% O2) was abrogated by HIF-1 siRNA but not by HIF2 or non-targeting (NS) siRNA (p < 0.001). These data indicate that enhanced
upregulation of GLS in hypoxic conditions occurs in an HIF-1 dependent manner.
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Figure 18. Effect of HIF-1α on GLS expression. RF24 and OVCAR8 cells were
transfected with HIF-1α or HIF-2α siRNA following exposure to 1% O2 for 24 hours.
GLS mRNA relative expression was then quantified and was significantly reduced with
HIF1α-siRNA but not with HIF2α-siRNA. Non-targeting siRNA (NS-siRNA) were used
for control. Error bars, SEM, *** p < 0.001. NS, non-significant.

GLS is ubiquitously expressed in both ovarian cancer and endothelial cell
lines
Before performing additional in vitro experiments to assess the effects of GLS
inhibition on ovarian cancer and endothelial cell lines, we first confirmed GLS
expression in eight ovarian cancer cell lines, including A2780, HeyA8, SKOV3,
OVCAR3, OVCAR4, OVCAR5, OVCAR8, and IGROV (Figure 19A). After culturing
the cells under normoxic conditions, GLS expression levels were noted to be highest
in the SKOV3 cells; therefore, we chose this cell line for further in vivo work. A similar
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GLS
GLS expression level to the SKOV3 cell line was observed in the parental line of
GLS2 resistance to
endothelial cells (RF24) as well as endothelial cells with an acquired

-Actin the RF24 and
AVA therapy with bevacizumab (RF24-bev, Figure 19B). Therefore,

RF24-bev cell lines were chosen to be utilized for additional in vitro investigations.
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Figure 19. Baseline GLS expression levels in ovarian cancer and
endothelial cells. (A) Western blot of GLS expression level in multiple
untreated ovarian cancer cell lines. (B) Western blot of GLS expression in
SKOV3 ovarian cancer cells and in both a parental and bevacizumabresistant endothelial cell line (RF24 and RF24-Bev, respectively).

Altered glutamine metabolism under hypoxic conditions enhances sensitivity
to GLS inhibition for both ovarian cancer and endothelial cells in vitro
After establishing that there was a high GLS expression in ovarian cancer cell
lines and that glutaminolysis was increased after the hypoxic stress imposed by AVA
treatment, we next targeted the increased reliance on glutamine as a potential
vulnerability. We did so with an internally synthesized glutaminase inhibitor (GLSi)
known as IACS-012031, subsequently referred to as GLSi throughout the text. This
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compound possesses the same chemical structure as the commercially available
and clinically tested GLS inhibitor called CB-839.43,49
First, the viability of OVCAR5, OVCAR8, and SKOV3 cells after culturing with
escalating doses of this GLSi was tested in vitro. Under normoxic conditions, the
viability of all three cell lines was inhibited in a time-dependent manner with a 3060% reduction in viability compared to untreated control cells (Figure 20A). Culture
of the parental RF24 endothelial cell line with AVA, GLSi, or both demonstrated a
greater reduction in cell viability when treated with GLSi as monotherapy compared
to AVA monotherapy under normoxic conditions, an effect that was even more
pronounced when the AVA and GLSi treatments were combined (36% vs 61% vs
6.3%, respectively; Figure 20B). Parental (RF24 par) and bevacizumab-resistant
RF24 (RF24-bev) cells demonstrated a dose-dependent inhibition of viability, with
the resistant cells exhibiting greater sensitivity to GLSi-based therapy than the
parental cells (Figure 20C). Specifically, the viability of the RF24-Bev cells was about
50% lower than that of RF24-par cells when cultured under hypoxic conditions with
the same dose of GLSi, with median half-maximal inhibitory concentrations (IC50) of
GLSi of 63.2 nM in RF24-par cells and 33.1 nM in RF24-Bev cells (Figure 20C).
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Figure 20. Hypoxia enhances sensitivity to GLS inhibition in both cancer and
endothelial cells in vitro. (A) The viability of three ovarian cancer cell lines (SKOV3,
OVCAR5, and OVCAR8) upon culture with GLSi [1.0 µM] monotherapy for 24-48
hours (p < 0.05). (B) The viability of the RF24-par endothelial cell line after culturing
with AVA or GLSi monotherapy or a combination of both therapies for 24 hours in
normoxic conditions (*p < 0.05, ***p < 0.001). Positive control: VEGF. (C) The viability
of RF24-par and bevacizumab-resistant RF24 cells (RF24-bev) after culture in
increasing concentrations of GLSi in either normoxic (20% O 2, black line) or hypoxic
(1% O2, red line) conditions.

Next, the angiogenic capability of the cells was assessed via a tube formation
assay with the RF24 endothelial cells which were cultured with GLSi for six hours
(Figure 21A and B). Under normoxia, the combination of GLSi and AVA resulted in
significantly less tube formation than did monotherapy with either drug (branch count
9.2 vs. 21.0 and 13.2, respectively; p < 0.01) or no treatment (control 27.4; p <
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0.001). This effect of reduced tube formation ability was even more pronounced in
hypoxia than in normoxia, again demonstrating that GLSi in combination with AVA
had a significantly greater reduction in tube formation than control therapy or
monotherapy with either GLSi or AVA (2.6 vs. 16.8, 14.9, and 8.2, respectively; p ≤
0.001). Ultimately, we observed increased sensitivity of both ovarian cancer and
endothelial cell lines to GLSi therapy under hypoxic conditions, an effect that was
even more pronounced when GLSi was combined with AVA, and particularly when
treating the endothelial cells that were resistant to AVA.
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Figure 21. Assessment of angiogenic potential of cells upon culturing with
AVA and GLSi in normoxic and hypoxic conditions. (A) Bright field
microscopic images at 50X showing the vessel loop formation and the effect of
bevacizumab (AVA) and GLSi monotherapy or in combination (AVA + GLSi) on
the angiogenic capability of RF24-par cell cultures in normoxia (20% O2) versus
hypoxia (1% O2). (B) Average branch counts of the vessel loops described in
(A) detected at 6 hours as measured in triplicate experiments; ** p < 0.01, *** p
< 0.001. VEGF, vascular endothelial growth factor; AVA, anti-VEGF antibody;
GLSi, glutaminase inhibitor.

GLSi has robust antitumor effects in combination with AVA in vivo
To further validate the in vitro findings of increased GLSi sensitivity in hypoxia
for both ovarian cancer and endothelial cells, we performed an in vivo experiment
with an orthotopic SKOV3ip1 ovarian cancer mouse model. In this experiment, we
randomized 60 nude mice to receive treatment with a vehicle control, AVA, GLSi, or
a combination of AVA and GLSi given at the same doses as in monotherapy (Figure
22).
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Figure 22. Experimental plan to investigate the efficacy of GLSi in vivo.
Schema of the in vivo experiment investigating the efficacy of GLSi treatment as
monotherapy or in combination with AVA treatment as compared to a vehicle control.

After seven weeks of treatment, the group of mice treated with the
combination of AVA and GLSi exhibited a robust antitumor effect as clearly seen on
gross necropsy (Figure 23) as well as quantifiably with a lower mean tumor weight
(0.05 g vs. 0.62 g and 0.64 g; p < 0.01) and tumor nodule number (3.3 vs. 12.8 and
13.9; p < 0.05) than those in the control and GLSi monotherapy groups, respectively
(Figure 24 A and B).
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Figure 23. Robust antitumor effect of GLSi combined with AVA as assessed
using gross necropsy. Gross inspection of tumor volume in an SKOV3ip1
mouse model after either no treatment (Control), bevacizumab (AVA), GLSi, or a
combination of bevacizumab and GLSi (GLSi + Bev). Tumor nodules are circled
in red outline. AVA, anti-VEGF antibody; GLSi, glutaminase inhibitor; Bev,
bevacizumab.
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Figure 24. Effect of GLSi combined with AVA on tumor burden in an
SKOV3ip1 mouse model at time of gross necropsy. (A) Nodule numbers and
(B) tumor weights of SKOV3ip1 mouse model after either no treatment (Control),
AVA, GLSi, or a combination of AVA and GLSi. Error bars, SD. *p < 0.05; **p <
0.01 (compared with the control group using the Student t-test). AVA, anti-VEGF
antibody; GLSi, glutaminase inhibitor; Bev, bevacizumab.
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The mean body weights were not significantly different between the
combination therapy, GLSi monotherapy, and control groups (23.6 g, 22.0 g, and
22.1 g, respectively; p = 0.16, Figure 25).
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Figure 25. Mouse body weight after treatment with AVA, GLSi or
combination therapy. Body weights of SKOV3ip1 mouse model after
randomization and treatment into one of four groups: control, AVA, GLSi,
or combination of bevacizumab plus GLSi therapy (AVA + GLSi); p =
0.16. AVA, anti-VEGF antibody; GLSi, glutaminase inhibitor.

The mean tumor vessel density, as assessed by IHC staining for the
endothelial cell marker CD31, in the combination therapy group was lower than in
the control, GLSi monotherapy, and AVA monotherapy groups (11 vs. 30, 15, and
15, respectively; p < 0.001, Figure 26A). The tumors in the combination group also
exhibited less cell proliferation than those in the GLSi and AVA monotherapy
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treatment groups or control groups, respectively, as assessed using Ki67 staining
(mean cell count/hpf: 108 vs. 151, 200, and 292; p < 0.01, Figure 26B).
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Figure 26. Immunohistochemistry analysis of vascular density and cellular
proliferation after treatment with AVA, GLSi or combination therapy. (A)
Blood vessel densities in ovarian tumor tissues harvested from mice in each
treatment group as assessed by endothelial cell marker CD31, *p < 0.05; ***p <
0.001. (B) Cell proliferation assay according to immunohistochemistry staining of
mouse ovarian cancer tissues with anti-Ki67, ** p < 0.01, ***p < 0.001, ****p <
0.0001. AVA, anti-VEGF antibody; GLSi, glutaminase inhibitor.

A subset of tissues obtained from this experiment (n = 5 per treatment group)
were also subjected to DESI-MS imaging analysis to investigate treatment-specific
alterations. The relative abundances of 74 features were significantly altered among
treatment groups, corresponding to a broad range of small metabolites and lipid
species (Figure 27, FDR < 5%).
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Figure 27. Heat map of altered metabolites seen after treatment with
AVA and GLSi mono- and combo-therapy. Intensity heat map for
metabolites selected by SAM as significantly altered among SKOV3ip1
tumors treated with a vehicle control, AVA, GLSi, or AVA + GLSi (FDR < 5%)
identified by DESI-MS imaging. Features were clustered using a Euclideandistance formula according to the average signal intensity of the
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corresponding m/z value measured from tumor-specific regions. The color
scale reflects z-score standard deviations from the mean relative abundance
measured for each ion. For fatty acid (FA) species, X:Y indicates the number
of carbons and double bonds, respectively.

In particular, an overall reduction in the relative abundances of glutamate,
malate, and hexose were identified in the combination therapy group compared to
the control or monotherapy groups with either GLSi or AVA, respectively (normalized
ion abundance of glutamate: 9.2, 13.1, 11.2 vs. 16.3, respectively; p < 0.05, Figure
28). The relative abundances of glutamine and citrate were significantly increased
in the GLSi monotherapy and combination groups compared to the control and AVA
monotherapy groups (normalized ion abundance of glutamine: 13.4 and 9.0 vs. 1.9
and 3.6, respectively p < 0.0001, Figure 28).
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Figure 28. Normalized ion abundance of key metabolites after combination
therapy with GLSi and AVA treatment. Median normalized intensity of the
relative abundance of glutamate metabolism and TCA cycle intermediates in
control, AVA (Bev) monotherapy, GLSi monotherapy, and combination therapy
groups (Combo) mice in the SKOV3ip1 orthotopic ovarian cancer model. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. AVA, anti-VEGF antibody; Bev,
bevacizumab.

When evaluating the conversion of pyruvate to lactate in the treatment
groups, we observed a reduced relative abundance of lactate relative to pyruvate in
all treatment groups compared to control, this was most notable in the GLSi
monotherapy and combination therapy groups, suggesting that the most substantial
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impact arising from GLSi therapy is on lactate metabolism (ion abundance of lactate:
70.9, 72.6, 85.7 vs. 101.4, p < 0.05, Figure 29 A and B). As expected, we observed
an overall reduction in the ratio of glutamine to glutamate conversion after GLSi
monotherapy and this reduction was sustained after combining GLSi with AVA
treatment (Figure 29 C). Moreover, the effect of reduced glutaminolysis observed
with GLSi and AVA combination therapy was more profound than the reduction we
observed in the AVA monotherapy of the AVA-sensitive tumor tissues (as seen in
Figure 16), suggesting that targeting both angiogenesis and the hypoxic adaptations
from it with both AVA and GLSi therapy significantly altered the tumor metabolism.
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Figure 29. DESI-MS ion images of ovarian tumors after treatment with
either AVA, GLSi, or combination therapy. (A) Representative DESI-MS ion
images of pyruvate, lactate, glutamine, and glutamate in mouse tumors after
treatment with a vehicle control, AVA, GLSi, or a combination of the two. H&E,
hematoxylin and eosin. (B) Median normalized intensity of the lactate to
pyruvate ratio in the control and treatment groups. *p < 0.05; ns, not significant.
(C) Median normalized intensity ratio of glutamate to glutamine in the control,
AVA monotherapy, GLSi monotherapy and combination therapy treatment
groups. Statistical significance was determined by Tukey’s HSD test, ***p <
0.001, ****p < 0.0001. Bev, bevacizumab anti-VEGF antibody; GLSi,
glutaminase inhibitor; ns, not significant.

Detection of GLSi therapy response using hyperpolarized magnetic resonance
spectroscopy
To further assess the therapeutic efficacy of GLSi therapy using a noninvasive approach, we performed hyperpolarized magnetic resonance spectroscopy
(HP-MRS) to quantify any metabolic changes in pyruvate-to-lactate metabolism
associated with this therapy in real-time. We did so using a total of 10 mice from the
aforementioned SKOV3ip1 model of adaptive resistance of ovarian cancer to AVA
therapy, with five mice receiving a vehicle control and five receiving GLSi. HP-MRS
is a novel technique that enhances the sensitivity of traditional magnetic resonance
imaging (MRI) up to 10,000-fold and facilitates a direct, non-invasive analysis of the
flux of pyruvate metabolism with spatial resolution of tumors in situ.66 Baseline MRI
Page | 60

images were obtained with mice under anesthesia to confirm tumor location in both
groups. After tail vein injection of hyperpolarized [1-13C] pyruvate as outlined in the
Materials and Methods, we quantitatively calculated each tumor’s normalized lactate
over pyruvate ratio, defined as the 13C resonance signal of lactate divided by the 13C
resonance signal of pyruvate over 60 seconds. Our analysis demonstrated that
pyruvate-to-lactate conversion in AVA-resistant tumors was significantly reduced in
vivo by GLSi therapy (0.337 vs. 0.178; p ≤ 0.001, Figure 30A, B). These findings are
concordant with the changes in relative abundance measured for pyruvate and
lactate using DESI-MS imaging in the experiment discussed above (Figure 29B).
This suggests that HP-MRS real-time imaging provides an early identification of
treatment effect from GLSi therapy.
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Figure 30. Detection of GLSi therapy response by HP-MRS. (A)
Representative T2-weighted MRI (coronal slice) and real-time in vivo 13C
magnetic resonance spectroscopy images of AVA-resistant ovarian tumors in
mice after intravenous hyperpolarized pyruvate injection for two treatment
groups: vehicle control (left) and GLSi (right) with spectra collected from the MRI
slabs on the ovarian tumors over two seconds. (B) The normalized
lactate/pyruvate ratios for vehicle- and GLSi-treated mice. ***p < 0.001. GLS,
glutaminase targeted treatment.
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GLS inhibition at the emergence of AVA resistance restores sensitivity in an
adaptive resistance model of ovarian cancer
After observing the robust antitumor effects of GLSi combined with AVA
therapy when given in combination up-front, we set out to determine whether GLSi
could restore sensitivity of ovarian cancer to AVA therapy if initiated after AVAresistance was established. For this experiment, we again used the SKOV3ip1
orthotopic mouse model but administered AVA monotherapy with bevacizumab after
tumor establishment and continued it until resistance was confirmed by
bioluminescence imaging (Figure 31).

Figure 31. Experimental plan to evaluate if AVA resistance can be restored
with GLSi therapy. Schema of the orthotopic SKOV3ip1 mouse model in which
AVA-resistance was established prior to the initiation of GLSi therapy. AVA, antiVEGF antibody (bevacizumab); GLSi, glutaminase inhibitor.
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After AVA-resistance was observed, we excluded the AVA-sensitive mice and
maintained all AVA-resistant mice on AVA therapy. We subsequently randomized
them to receive either a vehicle control or GLSi (both at 200 L via oral gavage twice
a day) until they became moribund. Initiation of GLSi therapy after establishment of
adaptive resistance to AVA therapy resulted in a partial abrogation of tumor growth
as evidenced by a 57% reduction in mean tumor weight (0.43 g vs. 1.01 g; p = 0.04)
and a 68% lower mean tumor nodule number in the GLSi group than in the control
group (5 vs. 15; p = 0.0003, Figure 32).
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Figure 32. AVA sensitivity is restored when GLSi therapy is administered
after AVA resistance is established. Mouse body weights, tumor weights, and
nodule numbers at the time of gross necropsy for mice treated with AVA
combined with a vehicle vs. those given AVA combined with GLSi. Error bars,
SD. *p< 0.05; *** p < 0.001 (compared with the control group using the Student ttest). AVA, anti-VEGF antibody; GLSi, glutaminase inhibitor; ns, not significant.
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The administration of GLSi therapy after the emergence of AVA resistance
not only provided an anti-tumor response, but it also resulted in a significant survival
benefit (median survival 69 vs. 65 days; p = 0.04). Continuing AVA therapy in the
resistant setting with a vehicle control was associated with a twofold increased risk
of death compared to treatment with AVA plus a GLSi (HR 2.069; 95% CI 1.03 4.15; Figure 33). We observed treatment toxicity in the AVA plus GLSi treatment
group, as evidenced by weight loss in this treatment group during the experiment.
However, mouse weight recovered with dose adjustments and was not significantly
different among the groups at the conclusion of the study (see Figure 32, left panel).
Our dose reduction mirrored a standard dose reduction protocol used in humans
whereby treatment was held for 48-72 hours after recognition of weight loss and the
dose was subsequently resumed at 2/3 the starting dose. In this experiment, the
starting dose was 200 uL of GLSi given via oral gavage twice daily (BID). The
reduced dose was therefore 200uL every morning and 100uL in the evening.
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Figure 33. Kaplan-Meier survival curve showing survival advantage with GLSi
therapy after AVA resistance is established. Nude mice were inoculated with the
SKOV3ip1 cell line and treated with AVA therapy until an adaptive resistance to it
emerged. Following AVA-resistance, the mice were continued on AVA therapy and
randomized to add on either a vehicle control or GLSi therapy. GLSi therapy
resulted in a survival advantage compared to vehicle control (p = 0.0408).
Continued therapy with AVA and a vehicle control was associated with a twofold
increase risk of death compared to AVA plus GLSi therapy (HR 2.069; 95%CI 1.03
– 4.15). AVA, anti-VEGF antibody; GLSi, Glutaminase inhibitor.
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DISCUSSION

Key Findings

Overall, the key finding of our investigation is that increased glutamine
metabolism is a metabolic adaptation to hypoxia that occurs in response to
resistance to AVA therapy in an orthotopic mouse model of ovarian cancer. We
exploited this metabolic vulnerability of glutamine dependence by combining AVA
therapy (bevacizumab) with GLSi which produced robust antitumor efficacy in both
in vitro and in vivo models of ovarian cancer.

Glutamine metabolism and regulation in response to AVA therapy in vitro
Reliance on glutamine metabolism for growth and development is an
established hallmark of cancer.22 However, the fate of glutamine and its metabolism
is complex.67 Previously, our lab reported the adaptive nature of the TME under
nutrient stress, and in particular, elucidated the role of reactive stromal cells under
glutamine deprivation and the ability of malignant tumors to harness carbon and
nitrogen from alternative sources to maintain glutamine stores.68 Use of these
glutamine stores is heterogeneous, as they can be consumed during protein
synthesis, serve as building blocks for the antioxidant glutathione, or be converted
into -ketoglutarate for TCA cycle anaplerosis via glutaminase (GLS).37,67 The role
of GLS in cancer growth and progression varies among human cancers and is
dependent on the cancer phenotype, with strong evidence of an oncogenic role for
GLS in colon, liver, and ovarian cancers but not in other cancers, such as non-small
cell lung cancer.67 Thus, GLS expression and the prognostic implications of its
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expression vary by cancer type, with higher GLS expression associated with worse
prognosis for ovarian cancer.64
Here we confirmed that GLS is ubiquitously expressed in a panel of ovarian
cancer cell lines and that hypoxia is positively correlated with GLS expression level.
Furthermore, we identified that one of the metabolic adaptations exhibited by both
ovarian cancer cells and endothelial cells in vitro after treatment with AVA therapy
is an upregulation of GLS expression. Moreover, we observed that this GLS
expression is regulated in an HIF-1α dependent manner. Further work is needed to
identify the transcription factor(s) and or promoters involved to determine whether
this effect is direct or indirect. However, given the well-documented association
between the hypoxic stress imposed by anti-angiogenic therapy and the increased
expression of HIF-1α23, these in vitro findings support the biologic plausibility of an
increased efficacy of targeted therapy with AVA when combined with a GLS inhibitor.
In fact, when we utilized a GLSi to target the hypoxia-mediated increase in GLS
expression after AVA treatment in vitro, we observed a significant vulnerability. This
was particularly the case in the AVA-resistant endothelial cell line, RF24-Bev.

Metabolic adaptations observed in AVA resistance
Using both LC-MS and DESI-MS we identified a number of metabolic
adaptations that occur in response to AVA treatment, and specifically after adaptive
resistance to it. The predominant changes were consistent across the LC-MS and
DESI-MS modalities as we noted a global upregulation of purine metabolism in the
AVA-resistant tumors compared to control tumors in both. Specifically, the
metabolites
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xanthine,

hypoxanthine,

xanthosine

and

3-
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ureidoprpionate were higher in the AVA-resistant group, compared to control tumors.
Given that glutamine is a required substrate for de novo synthesis of these purine
nucleotides,69 these findings support the hypothesis that blunting glutaminolysis by
inhibiting the GLS enzyme would be tumoricidal. When we evaluated the AVAresistant tumors with DESI-MS, we saw an increased expression of glutamate
relative to glutamine, further suggesting that GLS inhibition is a potential vulnerability
in AVA-resistance that could be targeted.

Examination of up-front combined therapy with GLSi and AVA with in vivo
models
We sought to validate the above in vitro observations with a series of in vivo
experiments. We first assessed the efficacy of GLSi therapy when given up-front in
combination with AVA therapy, prior to the emergence of AVA-resistance in a mouse
model of ovarian cancer. We noted a profound antitumor effect of GLSi in the
SKOV3ip1 ovarian cancer orthotopic mouse model. Upon DESI-MS analysis of the
tumor tissues from this experiment, we observed a significant decrease in anaerobic
metabolism and glutaminolysis as noted by an increased abundance of both
pyruvate and glutamine in the tissues obtained from mice treated with GLSi
monotherapy or combination therapy with GLSi and AVA. These findings were not
observed in the AVA monotherapy group but seen in the GLSi monotherapy and,
more strongly, in the combination of AVA and GLSi therapy. Taken together, this
suggests that it is the GLSi therapy, not AVA treatment, that is responsible for the
observed changes in the anaerobic metabolism of these tumors. Therefore, we
observed that GLSi therapy impacts the glutaminolysis pathway and has a more
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global effect on tumor metabolism, particularly when given in combination with AVA
therapy up-front, prior to AVA-resistance.

Assessment of the ability of GLSi to restore sensitivity to AVA therapy
Given the robust treatment response observed with up-front therapy, we next
set out to investigate whether GLSi therapy could restore sensitivity to AVA
treatment after AVA-resistance is established. This arena of therapy represents a
critical unmet need in the clinical setting. The reality is that nearly every patient
treated for ovarian cancer will be exposed to AVA therapy with bevacizumab at some
point along their cancer care journey because of its broad FDA approvals for firstline treatment for treatment in the recurrent or maintenance setting.14,25,27 As we
described, however, adaptive resistance to therapy develops nearly universally
within months of initiation of treatment and additional agents are needed to target
this population of patients with AVA-resistant disease.
In our established orthotopic mouse model of AVA-resistant disease59 where
80-90% of the mice receiving AVA treatment demonstrate an adaptive resistant to
it, we investigated the utility of GLSi therapy. Our results demonstrate a profound
antitumor efficacy of GLSi therapy administered in this setting with a reduction in
tumor burden by nearly a third. This was associated with a statistically significant
survival benefit. Similarly, we confirmed on DESI-MS that these AVA-resistant mice
also demonstrated a reduction in anaerobic metabolism, evidenced by a reduction
in pyruvate to lactate conversion, after treatment with GLSi therapy. These findings,
combined with our up-front evaluation of GLSi therapy discussed above, suggest
that GLSi therapy is of value when given in combination or sequentially with AVA.
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Therefore, GLSi therapy may prove to be beneficial in the clinical realm for patients
whose disease relapses after exposure to AVA or is AVA-resistant.

Assessment of therapeutic efficacy in real-time using HP-MRS
In addition to prospectively evaluating the efficacy of GLSi therapy in these
mouse models, we also sought to assess the therapeutic efficacy in real-time with
HP-MRS. This technology has been studied in multiple solid tumors as a novel
method of assessing treatment response in a manner that was previously
inaccessible to imaging.66 As it stands, demonstrating a treatment effect of either
standard or experimental treatments in patients with ovarian cancer is limited to
imaging studies such as computerized tomography (CT) or magnetic resonance
imaging (MRI) that are obtained several months after initiating treatment. These
techniques are focused on the detection of anatomical changes that occur on a
macroscopic level after treatment. Specifically, they use tumor size as a biomarker
for treatment response, which often occurs at a slow rate after starting therapy.70
Moreover, CT and MRI lack the ability to assess the functional alterations that occur
within the tumor prior to any changes in tumor volume that would be apparent on
imaging.70
In the present study, we utilized HP-MRS to assess therapeutic effect of the
GLSi treatment in our in vivo models. Using this functional imaging technique, we
were able to quantitatively evaluate the flux of pyruvate in the orthotopic tumors after
treatment with GLSi, thereby assessing the degree of anaerobic metabolism present
within them. We know that higher levels of anaerobic metabolism are associated
with more aggressive malignancies and, in essence, the level of pyruvate to lactate
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metabolism can serve as a biomarker of treatment response.71 In our study, we
observed that mice treated with GLSi had a reduced conversion of pyruvate to
lactate, an early marker of treatment efficacy in this model.
These preliminary studies further emphasize the potential of HP-MRS to be
applied in the clinical realm to allow for an assessment of treatment-efficacy in realtime. In doing so, HP-MRS in human patients could allow for identification of
treatment response, or a lack-thereof, in ovarian cancer. The benefit of HP-MRS
utilized for this purpose is that it could be performed at an earlier time point than
traditional CT or MRI assessment of macroscopic disease changes. Ultimately, this
would allow clinicians to identify a treatment failure sooner and focus their efforts on
alternative treatment strategies before the disease progresses even further.

Limitations
Limitations of this study include the utilization of a single ovarian cancer cell
line for the in vivo investigations. However, the author selected the SKOV3ip1
ovarian cancer cell line due to the expression profile of GLS making it the most
suitable candidate for study. Additionally, while the study provided a well-rounded
assessment of metabolic adaptations of ovarian cancer cell lines and tumors
exposed to hypoxic environments and GLSi treatment, definitive evaluation of the
mechanisms of resistance and therapy response(s) were limited and merit further
investigation. Furthermore, while we observed a clear relationship between HIF-1α
and GLS expression, the direct linkage between them has not been defined and
warrants further study. Lastly, this work did not seek to identify redundant or parallel
metabolic pathways at play within the realm of AVA resistance and it is important to
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identify these to better understand the impact of targeting GLSi in overcoming AVA
resistance.

Study Implications
Over the course of the past decade, ovarian cancer has remained the most
lethal gynecologic malignancy, but newer targeted therapies have allowed for a
longer survival than has ever been achieved before.72 Of these new treatments, AVA
therapy with bevacizumab has been a remarkable addition to the armamentarium of
options.28 However, the broad adoption of AVA therapy into the treatment schema
for both up-front therapy and for recurrent disease also means that there is a growing
population of patients that experience adaptive resistance to AVA and are
subsequently faced with limited treatment options moving forward.
Here we demonstrated that targeting the glutaminolysis pathway with GLS
inhibitor therapy in the AVA-resistant setting is a promising possibility. Although
additional studies are needed, we propose that glutaminolysis via the GLS enzyme
is a mechanism of resistance in patients treated with AVA therapy and GLSi
treatment would be beneficial in this population. Our work suggests that GLSi could
be efficacious in combination with AVA therapy up-front or in sequence after AVA
therapy is initiated. However, where it may provide the most benefit currently is for
the population of patients with recurrent, AVA-resistant disease.
The clinical testing of GLS inhibitors is still in its infancy with only a few trials
including women with ovarian cancer and, of those, there has been no direct focus
on treatment of AVA-resistant disease specifically. Recently, a phase I clinical trial
assessed the effect of a novel GLSi (IACS-6274) in patients with advanced ovarian
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cancer and demonstrated a disease control rate of 60% and durable stable disease
for at least six months in two patients with ovarian cancer.73,74 Within this trial, a
biomarker called asparagine synthetase (ASNS) was identified as a useful clinical
tool to predict response to GLSi therapy.73 The implications from our current study
suggest that the combination of AVA and GLSi treatment may produce enhanced
antitumor activity in at least some patients. Perhaps utilization of ASNS as a means
of molecular selection for patients to receive therapy could optimize the treatment
benefit. Based on the preclinical data generated as a part of this work, there is a
triple combination treatment trial with taxane chemotherapy, AVA and GLSi being
finalized with the goal to start within six months. This is an exciting development that
will also allow for interrogation of tumor samples while patients are on treatment. As
these clinical trials mature and progress into phase II and phase III studies, it will be
interesting to see the degree and durability of treatment responses.

Future Directions
The next conceptual advance in response to the data presented here requires
the development of a phase I clinical trial to test the safety profile and efficacy of
GLSi treatment specifically within AVA-resistant ovarian cancer. Toxicity will have to
be closely monitored considering our observations from our in vivo experiments. It
will also be important to carefully examine the response to therapy in these patients
in order to better detect biomarkers. Our in vivo analysis of therapeutic efficacy by
HP-MRS invite further development in this realm as a potential avenue for real-time
investigation of treatment response far before it can be detected on CT or MRI
imaging.
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CONCLUSIONS
In the present study, we identified ubiquitous expression of GLS in ovarian
cancer cell lines and confirmed that treatment with AVA (bevacizumab) is associated
with an upregulation of GLS as a metabolic adaptation occurring in both cancer cells
and in endothelial cells where AVA functions. This upregulation occurs in an HIF-1
dependent fashion in both cell types and we targeted this hypoxia-mediated increase
in GLS expression using GLSi therapy. In vitro, we observed significant vulnerability
of bevacizumab-resistant RF24 cells (RF24-Bev) to this therapy and noted a
profound antitumor effect of GLSi in the SKOV3ip1 ovarian cancer orthotopic mouse
model of adaptive resistance to AVA. Of note, we demonstrated efficacy of GLSi
when given together with AVA as up-front therapy and when added to AVA after the
emergence of resistance. Our in vivo studies suggest that this combination therapy
is well tolerated.
In sum, we showed that GLSi therapy, when combined with AVA treatment,
has robust antitumor effects in preclinical models. This combined therapy warrants
further investigations evaluating biologic markers that could predict response of
ovarian cancer to GLSi therapy. In addition, future studies evaluating the
combination of GLSi with additional chemotherapy drugs are warranted. Our findings
provide hope of expanding the utility and efficacy of AVA in the clinical treatment of
ovarian cancer, particularly in the AVA-resistant setting.
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